Navigation Links
ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Date:3/18/2011

as designated an orphan medicinal product on October 8, 2009. Upon granting of a Centralized Marketing Authorization and retention of the orphan medicinal product designation, Cinryze would be entitled to a period of 10 years market exclusivity in respect of the approved therapeutic indication. This 10-year market exclusivity period could be extended cumulatively to 12 years when the results of all studies conducted in compliance with an agreed pediatric investigation plan are completed and included in the summary of product characteristics.

About Cinryze® (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product.  In the U.S., Cinryze was approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  In the E.U., the recommended indication is for treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment.

Severe hypersensitivity reactions to Cinryze may occur.  Thrombotic events have occurred in patients receiving Cinryze for routine prophylaxis, and in patients receiving off-label high dose C1 inhibitor therapy.  Monitor patients with known risk factors for thrombotic events.  With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.  <
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 PharmaPoint: Type 1 Diabetes - Global Drug ... 1 diabetes (T1D) is an autoimmune disease that permanently destroys ... body can no longer produce insulin. Over the last 90 ... no other treatment can be offered to a patient who ... with different times of action - long-acting as well as ...
(Date:5/27/2015)... The prevalence of cardiovascular disease in ... population and changes in consumption concept, dietary habit, way ... after year, thereby promoting the development of domestic percutaneous ... China totaled 454,505 in 2013, up 16.9% ... industry there was worth RMB20.12 billion. At present, ...
(Date:5/27/2015)... , May 27, 2015 ... announced the addition of the  "Asia Pacific ... Forecasts (2014 - 2019)"  company profile ... http://photos.prnewswire.com/prnh/20130307/600769) , , ,Ultrasound is a type ... to look at body parts and structures ...
Breaking Medicine Technology:PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4China Interventional Cardiovascular Device Industry Report, 2014-2017 2China Interventional Cardiovascular Device Industry Report, 2014-2017 3Asia Pacific Ultrasound Devices Market Report 2015 - Growth, Trends And Forecasts 2014 - 2019 2
... , , TOKYO ... Daiichi Sankyo Company, Limited (TSE: 4568), announced today that ... for edoxaban, its investigational oral Factor Xa inhibitor. This new ... and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) ...
... , , SOMERSET, N.J. , Feb. ... trials in patients with acute low back pain (ALBP) who ... functionality and reduced disability after three days of treatment, as ... being presented this week at the 26th annual meeting of ...
Cached Medicine Technology:Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 2Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 3Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 4Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 5SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 2SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 3SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 4SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 5
(Date:5/27/2015)... 27, 2015 CompanionDx announced ... somatic genomic analysis in personalized cancer therapy: Non-small cell ... American Society of Clinical Oncology (ASCO) as part of ... Chicago. , The molecular and clinical data used for ... (TCGA) database. The study reports improved patient outcomes from ...
(Date:5/27/2015)... IL (PRWEB) May 27, 2015 On ... North-based advertising agency, will partner with LifeSource to host ... event will take place in a LifeSource donor coach ... a.m. to 4:00 p.m. , Demand for whole blood ... in Illinois, during the summer months. LifeSource requires approximately ...
(Date:5/27/2015)... 27, 2015 This is a ... of the Omega-3 industry. The report provides a ... applications and industry chain structure. The Omega-3 market ... development trends, competitive landscape analysis, and key regions ... Camanchaca Fishing Company, Seadragon Marine Oils, Norwegian Fish ...
(Date:5/27/2015)... May 27, 2015 SonarMD, ... SonarMD Platform, a first-of-its kind, cloud-based algorithmic ... patients with chronic gastrointestinal disease. , Developed ... the application allows physicians to monitor their ... ongoing use of electronic health assessment surveys. ...
(Date:5/27/2015)... 2015 “Heroin has never been more plentiful ... are coming from,” says Harford County Sheriff Jeff Gahler, as ... In the surging heroin related incidents in Baltimore, police resources ... to prevent heroin addiction and subsequent abuse before it turns ... Rehab Baltimore is a drug and alcohol rehab facility specializing ...
Breaking Medicine News(10 mins):Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 3
... involved in a unique kidney swap operation. Chandler's husband ... not match. The same is the case with Torres ... Torres and his wife's with Chandler's husband. Hence they ... that is to be performed today at University of ...
... SARS affected South-East Asia two years ago, by installing ... designing a new system that could help early// diagnosis ... it. ,The company has sought the permission ... to Prime Minister and the Chief Minister, for installing ...
... gay men to donate blood in Aberdeen. ,Students of ... the ban overturned. They also// warned that the current situation ... ,As part of the protest, students will hand out cards ... ,Those behind the campaign say they do not want ...
... patients, where the first bird flu case was reported, proved ... residents 94 were cleared off the disease. // ... be known Friday, an official statement issued here said. ... now. ,"Ninety-five samples have been tested at NICD ...
... Jharkhand to preserve the rare herbal plants that are on the ... Ramdev in setting up the herbarium.// ,The Tribal Research ... Bariatu in Ranchi with an initial investment of Rs.150,000. Baba Ramdev's ... ,"We have started work to set up the herbarium. The ...
... Diomande, a childhood dancer, from the tender age of 4, known ... setback to his health. No, this was not an accidental fall ... ,On Thursday, Mr Diomande collapsed soon after a ... anthrax spores. This might have occurred after stretching the animal skins ...
Cached Medicine News:Health News:Bird Flu Test Results Negative: India 2
Pioneer in 1985 by launching the 1st adjustable pressure valve. More than 55,000 SOPHY adjustable pressure valves implanted throughout the world between 1985 and 2003....
Codman Hakim Programmable micro offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often change over the course of...
Codman Hakim Programmable valve cylindrical with PrechamberInline offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition wi...
... Osteopal V is a low viscosity ... use in vertebroplasty. The bone cement is ... stabilization purposes. Osteopal V is used for ... concentration of zirconium dioxide is included in ...
Medicine Products: